je.st

Home › alzheimers disease

Tag: alzheimers disease

PM2.5, O3 pollution associated with development of Alzheimers disease; new study identifies evolving axonal damage

2018-12-23 11:57:13| Green Car Congress

PET scans can stage Alzheimers disease in living people

2016-03-08 17:00:04| Extremetech

For a while we thought amyloid plaques were the smoking gun in Alzheimer's disease, but new research out of Berkeley has shown us some surprising details about the spread of Alzheimer's through the brain - and used PET imaging to stage the disease in living people for the first time.

Tags: people living stage pet

Amgen, Novartis collaborate for Alzheimer's disease and migraine programs

2015-09-02 11:50:57| Biotech - Topix.net

Amgen today announced a neuroscience collaboration with Novartis in the areas of Alzheimer's disease and migraine. The collaboration accelerates Amgen's potential entry into Alzheimer's disease by teaming up with Novartis on a differentiated and genetically validated Alzheimer's disease program directed at genetically predisposed individuals at risk of developing Alzheimer's disease.

Tags: programs disease collaborate migraine

Merck Advances Development Program for Investigational Alzheimers Disease Therapy, MK-8931

2013-12-10 13:00:00| Merck.com - Product News

Dateline City: WHITEHOUSE STATION, N.J. Data Monitoring Committee recommends continuation of Phase II/III EPOCH study in mild to moderate disease patients Merck also plans to initiate dosing in Phase III study of prodromal disease patients WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today provided an update on the development program for MK-8931, a novel investigational oral -amyloid precursor protein site-cleaving enzyme (BACE) inhibitor. Language: English Contact: MerckMedia:Caroline Lappetito, 267-305-7639Justine OMalley, 908-423-2021orInvestors:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: development program disease therapy